A detailed history of Engineers Gate Manager LP transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Engineers Gate Manager LP holds 8,268 shares of HALO stock, worth $473,012. This represents 0.01% of its overall portfolio holdings.

Number of Shares
8,268
Previous 33,763 75.51%
Holding current value
$473,012
Previous $1.37 Million 68.54%
% of portfolio
0.01%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $963,965 - $1.34 Million
-25,495 Reduced 75.51%
8,268 $432,000
Q1 2024

May 15, 2024

SELL
$33.68 - $41.95 $1.75 Million - $2.18 Million
-51,874 Reduced 60.57%
33,763 $1.37 Million
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $424,963 - $536,943
12,754 Added 17.5%
85,637 $3.17 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $1.98 Million - $2.4 Million
54,439 Added 295.16%
72,883 $2.78 Million
Q2 2023

Aug 14, 2023

SELL
$30.28 - $38.74 $732,109 - $936,655
-24,178 Reduced 56.73%
18,444 $665,000
Q1 2023

May 15, 2023

BUY
$32.86 - $55.7 $1.4 Million - $2.37 Million
42,622 New
42,622 $1.63 Million
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $830,365 - $1.07 Million
22,232 New
22,232 $978,000
Q2 2021

Aug 16, 2021

SELL
$38.84 - $51.31 $442,776 - $584,934
-11,400 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$39.51 - $51.45 $82,931 - $107,993
2,099 Added 22.57%
11,400 $475,000
Q4 2020

Feb 16, 2021

SELL
$25.81 - $43.62 $289,046 - $488,500
-11,199 Reduced 54.63%
9,301 $397,000
Q3 2020

Nov 16, 2020

BUY
$25.74 - $29.63 $208,494 - $240,003
8,100 Added 65.32%
20,500 $539,000
Q2 2020

Aug 17, 2020

BUY
$16.25 - $26.81 $201,500 - $332,444
12,400 New
12,400 $332,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $7.97B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Engineers Gate Manager LP Portfolio

Follow Engineers Gate Manager LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

News

Stay updated on Engineers Gate Manager LP with notifications on news.